



## **OvaScience to Present at the 36th Annual J.P. Morgan Healthcare Conference**

January 4, 2018

WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 4, 2018-- OvaScience? (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today announced that Christopher Kroeger, M.D., Chief Executive Officer of OvaScience, will present a corporate overview at the 36<sup>th</sup> Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018 at 11:00 a.m. PT ( 2:00 p.m. ET) at the Westin St. Francis Hotel in San Francisco, California.

A live audio webcast of the presentation can be accessed by visiting the investor section of the company's website at [www.ovascience.com](http://www.ovascience.com). A replay of the webcast will be archived on the OvaScience website for 30 days following the presentation.

### **About OvaScience?**

OvaScience?, Inc. (NASDAQ:OVAS) is a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility. Each OvaScience treatment is based on the Company's proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPC?) cells – immature egg cells found inside the protective ovarian lining. OvaScience is developing OvaPrime?, which could increase a woman's egg reserve and OvaTure?, a potential *in vitro* fertilization (IVF) treatment that could help a woman produce new, fertilizable eggs without hormone injections. OvaScience's AUGMENT? treatment, a fertility option designed to improve IVF success rates, is available in certain IVF clinics in Canada and Japan. OvaScience treatments are not available in the U.S. For more information, visit [www.ovascience.com](http://www.ovascience.com).

###

View source version on businesswire.com: <http://www.businesswire.com/news/home/20180104005233/en/>

Source: OvaScience

OvaScience, Inc.  
Jennifer Viera, 617-420-8748  
[jviera@ovascience.com](mailto:jviera@ovascience.com)